Cancer prevention and delay are as important as cure

Lancet Oncology

Volumn 4, Issue 2, 2003, Pages 72-73

  Gescher, Andreas J ^a   Sharma, Ricky A ^a   Steward, William P ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BIOLOGICAL MARKER; SELENIUM; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SUSCEPTIBILITY; CANCER THERAPY; CHEMOPROPHYLAXIS; DOCTOR PATIENT RELATION; HIGH RISK PATIENT; HUMAN; MASTECTOMY; MATHEMATICAL MODEL; NOTE; OUTCOMES RESEARCH; OVARIECTOMY; OVARY CANCER; PATIENT CARE; PRECANCER; PRIORITY JOURNAL;

EID: 0037319080     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)00976-8     Document Type: Note

References (5)

1. Lancet Oncology. Is prevention really better than cure? Lancet Oncol 2002; 3: 645.
2. Berfeldt K, Rydh B, Granath F, et al. Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. Lancet 2002; 360: 891-94.
3. Gescher A, Sharma RA, Steward WP. Cancer chemoprevetion by dietary constituents: a salutary tale of failure and promise. Lancet Oncol 2001; 2: 371-79.
4. Lippman SM, Hong W K. Cancer prevention by delay - commentary. Clin Cancer Res 2002; 8: 305-13.
5. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probalities of developing breast cancer for white females who are being exained annually. J Natl CAncer Inst 1989; 81: 1879-86.